Company Overview
SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by developing innovative therapies. The SCYNEXIS team has extensive experience in the life sciences industry, discovering and developing more than 30 innovative medicines over a broad range of therapeutic areas.
Recent News
SCYNEXIS Reports Third Quarter 2024 Financial Results and Provides Corporate Update
SCYNEXIS to Participate in the 2024 Maxim Healthcare Virtual Summit
SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at IDWeek 2024
Stock Overview
Symbol
SCYX
Exchange
Nasdaq
Market Cap
44.78m
Last Price
$1.18
52-Week Range
$1.15 - $3.07
11/20/2024 09:00 PM EST